Complications in patients with cancer-associated thrombosis on tinzaparin by cancer site and frailty: a pooled analysis
Abstract
ABSTRACT: Cancer-associated thrombosis (CAT) is a frequent and severe complication of malignancy. Although patients undergo anticoagulation, risks of recurrent venous thromboembolism (VTE) and major bleeding (MB) remain substantial, but data are limited according to specific tumor sites and in patients with frailty. Our objective was to evaluate 6-month incidences of recurrent VTE, MB, and death in patients with CAT treated with tinzaparin, and to assess the influence of tumor site and frailty on these risks. Individual patient-level data from 1413 patients were pooled from 3 prospective cohort studies and the tinzaparin arm of a randomized controlled trial. Frailty was defined as age of ≥75 years, creatinine clearance of
Fields of Study & Subjects
Venous Thromboembolism Diagnosis and Management
Chemotherapy-induced cardiotoxicity and mitigation
Antiplatelet Therapy and Cardiovascular Diseases
Publication details
- Journal / source
- Blood Advances
- Publisher
- American Society of Hematology
- Volume
- 10
- Issue
- 9
- Pages
- 3292–3300
- Publication date
- 18 February 2026
- Language
- EN